Last reviewed · How we verify

NCT04307927

Lifetech LAmbre™ Left Atrial Appendage Closure System Post-Market Registry

Status unknown Last updated 29 November 2022
What this trial tests

trial in Atrial Fibrillation in 100 participants. Status unknown.

Timeline
14 March 2020
Primary endpoint
31 December 2024
31 December 2025

Quick facts

Lead sponsorLifetech Scientific (Shenzhen) Co., Ltd.
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date14 March 2020
Primary completion31 December 2024
Estimated completion31 December 2025
Sites1 location across Germany

Conditions studied

Sponsor

Lifetech Scientific (Shenzhen) Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single-center, single-arm, prospective, post-market study of LAmbre™ LAA Closure System. To evaluate immediate and long term procedural success of Lifetech LAmbre™ occluders in patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Lifetech Scientific (Shenzhen) Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04307927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing